New York, USA, June 12, 2025 (GLOBE NEWSWIRE) -- Giant-cell Arteritis Market Heats up with AbbVie’s RINVOQ Approval | DelveInsight The FDA has approved AbbVie’s RINVOQ (upadacitinib) for the treatment of giant cell arteritis, making it the ninth approved indication for the drug. This also marks the first time an oral JAK inhibitor has been approved for this prevalent form of vasculitis in Western countries. RINVOQ’s approval has sparked competition among other pharmaceutical companies in the giant cell arte ...